Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Investigational 2 mg Dose of Ozempic (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial

firstwordpharmaJune 28, 2021

Tag: Ozempic , Semaglutide , Novo Nordisk

PharmaSources Customer Service